Substance / Medication

Rabeprazole sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Identification, isolation and characterization of new impurity in rabeprazole sodium.
Rao P Sreenivasa, Ray Uttam Kumar, Gupta P Badarinadh et al. · J Pharm Biomed Anal · 2010
PMID: 20153594Observational
Development and validation of a dissolution test for rabeprazole sodium in coated tablets.
Garcia Cassia V, Paim Clesio S, Steppe Martin et al. · J Pharm Biomed Anal · 2006
PMID: 16513316Observational
Development of Simple Fluorescence Spectrometry With Blue Emissive VC MXene for Selective Detection of Rabeprazole Sodium in Pharmaceutical Samples.
Singh Pooja Dharni Dhar, Murthy Z V P, Park Tae Jung et al. · Luminescence · 2025
PMID: 41392354Other
Repurposing rabeprazole sodium as an anti-Clostridium perfringens drug by inhibiting perfringolysin O.
Wang Guizhen, Liu Yan, Deng Le et al. · J Appl Microbiol · 2023
PMID: 38017630Other
Identification and genotoxicity evaluation of potential impurities in rabeprazole sodium usingandanalyses.
Du Yi, Wu Yinnan, Liu Yang et al. · Drug Chem Toxicol · 2022
PMID: 33829945Other
Improved quantitative determination of (R)- and (S)-rabeprazole sodium and its metabolites in rat plasma by LC-MS/MS and its application to a toxicokinetic study.
Guo Jianman, Ma Xiaoyuan, Bu Fanlong et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2024
PMID: 38141290Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rabeprazole sodium (substance)
SNOMED CT
387013009
UMLS CUI
C0732569

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.